TetraVax-DV Vaccine - Admixture TV005

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Dengue

Phase 1

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

CompletedNCT01436422

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2011-08-31End: 2014-03-31Updated: 2015-08-20

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

CompletedNCT01506570

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2011-12-31End: 2013-09-30Updated: 2015-08-20

Related Papers

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination

PLoS neglected tropical diseases2017-05-0899 citations

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

The Journal of Infectious Diseases2015-03-22195 citations